Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 [Yahoo! Finance]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Yahoo! Finance
patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events . A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI ® FAKZYNJA ® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inh
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Business Wire
- Verastem (VSTM) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.MarketBeat
- Vectoring In On Verastem [Seeking Alpha]Seeking Alpha
- Verastem (VSTM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VSTM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
VSTM
Earnings
- 3/4/26 - Beat
VSTM
Sec Filings
- 4/9/26 - Form DEF
- 3/27/26 - Form SCHEDULE
- 3/23/26 - Form 4
- VSTM's page on the SEC website